Intra-Cellular Therapies Inc (ITCI) Director Sells $456,000.00 in Stock

Share on StockTwits

Intra-Cellular Therapies Inc (NASDAQ:ITCI) Director Joel S. Marcus sold 25,000 shares of the stock in a transaction on Friday, November 9th. The shares were sold at an average price of $18.24, for a total value of $456,000.00. Following the completion of the sale, the director now owns 21,671 shares of the company’s stock, valued at $395,279.04. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Intra-Cellular Therapies stock opened at $15.79 on Friday. Intra-Cellular Therapies Inc has a 1-year low of $14.31 and a 1-year high of $25.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.09. As a group, equities research analysts anticipate that Intra-Cellular Therapies Inc will post -3.05 earnings per share for the current fiscal year.

Several brokerages recently issued reports on ITCI. Leerink Swann reiterated an “outperform” rating on shares of Intra-Cellular Therapies in a report on Friday, October 19th. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday. ValuEngine downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Thursday. Royal Bank of Canada reiterated a “buy” rating and issued a $35.00 price target on shares of Intra-Cellular Therapies in a report on Friday, August 3rd. Finally, Cantor Fitzgerald set a $32.00 price target on Intra-Cellular Therapies and gave the company a “buy” rating in a report on Tuesday, October 23rd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $28.25.

Several institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN grew its stake in shares of Intra-Cellular Therapies by 13.8% during the first quarter. Wells Fargo & Company MN now owns 25,352 shares of the biopharmaceutical company’s stock valued at $534,000 after acquiring an additional 3,065 shares in the last quarter. Public Employees Retirement Association of Colorado grew its stake in shares of Intra-Cellular Therapies by 127.8% during the third quarter. Public Employees Retirement Association of Colorado now owns 5,687 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 3,190 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of Intra-Cellular Therapies by 53.0% during the second quarter. Cubist Systematic Strategies LLC now owns 9,641 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 3,339 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Intra-Cellular Therapies by 19.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 20,462 shares of the biopharmaceutical company’s stock valued at $362,000 after acquiring an additional 3,400 shares in the last quarter. Finally, GSA Capital Partners LLP grew its stake in shares of Intra-Cellular Therapies by 10.0% during the second quarter. GSA Capital Partners LLP now owns 48,594 shares of the biopharmaceutical company’s stock valued at $859,000 after acquiring an additional 4,400 shares in the last quarter. Institutional investors own 70.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Intra-Cellular Therapies Inc (ITCI) Director Sells $456,000.00 in Stock” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2018/11/16/intra-cellular-therapies-inc-itci-director-sells-456000-00-in-stock.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

See Also: Index Funds

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply